BOSTON (Thomson Financial) - Abiomed Inc. Monday said it has received a
501(k) clearance from the Food and Drug Administration for its Impella 2.5
cardiac assist device.
The 510(k) clearance allows Abiomed to begin selling the heart pump to
cardiologists at about 1,700 heart hospitals in the U.S., the company said.
Shares of the Danvers, Mass.-based medical device maker closed Friday at
$14.69.
Casey Logan
cl/jw
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|